BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 29223477)

  • 1. Immuno-oncology from the perspective of somatic evolution.
    González S; Volkova N; Beer P; Gerstung M
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):75-85. PubMed ID: 29223477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immuno-oncology-101: overview of major concepts and translational perspectives.
    Allard B; Aspeslagh S; Garaud S; Dupont FA; Solinas C; Kok M; Routy B; Sotiriou C; Stagg J; Buisseret L
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):1-11. PubMed ID: 29428479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humanized Mice for the Study of Immuno-Oncology.
    De La Rochere P; Guil-Luna S; Decaudin D; Azar G; Sidhu SS; Piaggio E
    Trends Immunol; 2018 Sep; 39(9):748-763. PubMed ID: 30077656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor resistance to specific lysis: a major hurdle for successful immunotherapy of cancer.
    Chouaib S; Meslin F; Thiery J; Mami-Chouaib F
    Clin Immunol; 2009 Jan; 130(1):34-40. PubMed ID: 19013109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pooled in vivo screens for cancer immunotherapy target discovery.
    Lane-Reticker SK; Manguso RT; Haining WN
    Immunotherapy; 2018 Mar; 10(3):167-170. PubMed ID: 29370725
    [No Abstract]   [Full Text] [Related]  

  • 6. Epigenetics and immunotherapy: The current state of play.
    Dunn J; Rao S
    Mol Immunol; 2017 Jul; 87():227-239. PubMed ID: 28511092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immune response and cancer].
    El Hage F; Abouzahr-Rifai S; Meslin F; Mami-Chouaib F; Chouaib S
    Bull Cancer; 2008 Jan; 95(1):57-67. PubMed ID: 18230571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour escape mechanisms and their therapeutic implications in combination tumour therapy.
    Bhutia SK; Mallick SK; Maiti TK
    Cell Biol Int; 2010 Apr; 34(5):553-63. PubMed ID: 20384587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of oncolytic virus immunotherapies to subvert cancer immune evasion.
    Workenhe ST; Verschoor ML; Mossman KL
    Future Oncol; 2015; 11(4):675-89. PubMed ID: 25686121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic Approaches to Understanding Response and Resistance to Immunotherapy.
    Braun DA; Burke KP; Van Allen EM
    Clin Cancer Res; 2016 Dec; 22(23):5642-5650. PubMed ID: 27698000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy.
    Adachi K; Tamada K
    Cancer Sci; 2015 Aug; 106(8):945-50. PubMed ID: 25981182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer Nanomedicine: Lessons for Immuno-Oncology.
    Sengupta S
    Trends Cancer; 2017 Aug; 3(8):551-560. PubMed ID: 28780932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy.
    Mandal R; Chan TA
    Cancer Discov; 2016 Jul; 6(7):703-13. PubMed ID: 27107038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions.
    Sucker A; Zhao F; Pieper N; Heeke C; Maltaner R; Stadtler N; Real B; Bielefeld N; Howe S; Weide B; Gutzmer R; Utikal J; Loquai C; Gogas H; Klein-Hitpass L; Zeschnigk M; Westendorf AM; Trilling M; Horn S; Schilling B; Schadendorf D; Griewank KG; Paschen A
    Nat Commun; 2017 May; 8():15440. PubMed ID: 28561041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The intricate dance of tumor evolution: Exploring immune escape, tumor migration, drug resistance, and treatment strategies.
    Guo X; Bian X; Li Y; Zhu X; Zhou X
    Biochim Biophys Acta Mol Basis Dis; 2024 Apr; 1870(4):167098. PubMed ID: 38412927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Principles of immunotherapy.
    Olszanski AJ
    J Natl Compr Canc Netw; 2015 May; 13(5 Suppl):670-2. PubMed ID: 25995426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aneuploidy as a promoter and suppressor of malignant growth.
    Vasudevan A; Schukken KM; Sausville EL; Girish V; Adebambo OA; Sheltzer JM
    Nat Rev Cancer; 2021 Feb; 21(2):89-103. PubMed ID: 33432169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Of Mice, Dogs, Pigs, and Men: Choosing the Appropriate Model for Immuno-Oncology Research.
    Overgaard NH; Fan TM; Schachtschneider KM; Principe DR; Schook LB; Jungersen G
    ILAR J; 2018 Dec; 59(3):247-262. PubMed ID: 30476148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic basis for response to cancer immunotherapy.
    Gruber K
    Lancet Oncol; 2017 Sep; 18(9):e521. PubMed ID: 28826592
    [No Abstract]   [Full Text] [Related]  

  • 20. Models for Immuno-oncology Research.
    Cancer Cell; 2020 Aug; 38(2):145-147. PubMed ID: 32781038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.